Rubens R D, Hayward J L
Cancer. 1980 Dec 15;46(12 Suppl):2922-4. doi: 10.1002/1097-0142(19801215)46:12+<2922::aid-cncr2820461435>3.0.co;2-d.
In a consecutive series of 191 patients with advanced breast cancer, the response rate to endocrine treatment was 46/136 (34%) in estrogen receptor positive (ER+) patients, compared with 5/55 (9%) in estrogen receptor negative (ER-) patients (P < 0.01). In a retrospective analysis of 47 patients, the response rate to cytotoxic chemotherapy was 20/33 (62%) for ER+ tumors and 8/14 (57%) for ER-. It is concluded that ER+ tumors have a significantly higher chance of responding to endocrine therapy than do ER- tumors, but that receptor status is not a determinant of response to cytotoxic chemotherapy.
在一组连续的191例晚期乳腺癌患者中，雌激素受体阳性（ER+）患者对内分泌治疗的缓解率为46/136（34%），而雌激素受体阴性（ER-）患者为5/55（9%）（P<0.01）。在对47例患者的回顾性分析中，ER+肿瘤对细胞毒性化疗的缓解率为20/33（62%），ER-肿瘤为8/14（57%）。得出的结论是，ER+肿瘤对内分泌治疗有反应的可能性明显高于ER-肿瘤，但受体状态不是细胞毒性化疗反应的决定因素。
